


A.M. Sánchez García, A. Andújar Mateos, M. Llinares Esquerdo, L. Soriano-Irigaray, R. Antón Torres, A. Navarro Ruiz  
Hospital General Universitario de Elche, Pharmacy Department, Elche, Spain.

## OBJECTIVES


To compare the effectiveness of abiraterone acetate (AA) and enzalutamide (EZD) in patients with metastatic castration resistant-prostate cancer (mCRPC).

## METHODS



The statistical tests used, through the IBM SPSS® Statistics 23 program, were: **t-student** to assess the **PFS** and the **Chi-Square** and **Fisher exact test** to assess the **PSA response**.

## RESULTS



## CONCLUSIONS

Abiraterone acetate and enzalutamide have the same effectiveness measured as PFS and PSA reduction in our study. Even so, it is necessary to take into account the low number of patients treated, being necessary more studies that confirm this comparison.